Tineco Ushers the Vacuum Industry into the Age of Intelligence with the PURE ONE S12 Premium Vacuum
![](https://i1.wp.com/picante.today/wp-content/uploads/2019/05/PUREONEImage.jpg?fit=150%2C150&ssl=1)
First launched in China in March 2019, Tineco’s smart cordless vacuum
is now available in the U.S. and is equipped with smart suction
optimization, smart battery management, smart filter self-cleaning tool,
smart noise control, smart app integration, and an all-in-one LED
display.
SAN FRANCISCO–(BUSINESS WIRE)–Tineco,
the premium smart electrical appliance brand, today announced the
addition of PURE ONE to its industry-defining smart, cordless vacuum
cleaner lineup. First released in China earlier this year on March 13,
the PURE ONE series, including its three models the PURE ONE S12 M, PURE
ONE S12 and PURE ONE S12 Plus, are now available on Amazon for U.S.
consumers. Tineco’s smart vacuum cleaners have pioneered vacuum
technology from a functional device to an intelligent one, setting a new
standard for the vacuum industry. Unlike anything on the market, PURE
ONE leverages artificial intelligence to solve consumer pain points for
most vacuum cleaners, allowing for smarter, deeper, quieter, and longer
cleans.
With 21 years in the vacuum industry and hundreds of patents filed,
Tineco has proven to be a key driver in the evolution of vacuum
cleaners. PURE ONE is another premier appliance resulting from the
company’s leadership and continued investment in R&D. Tineco has already
flourished in overseas markets, most recently entering the U.S. in May
2018 with its best-selling A Series cordless stick vacuums. According to
a November 2018 Stackline report, Tineco is already the No. 2 top
selling cordless stick vacuum on Amazon U.S.since then, with market
share continuing to grow.
The fast growth and impressive customer response is largely attributed
to the high performance of Tineco’s brand, and the company’s commitment
to providing every consumer around the globe with the opportunity to
“Live Easy, Enjoy Life” with a complete home cleaning experience. During
Tineco’s PURE ONE launch in China, Jianhua Zhuang, CEO of Tineco said,
“Tineco is dedicated to infusing the concept of ‘Live Easy, Enjoy Life’
into product R&D and user experience, leveraging technology with care
and humanity to solve every small need in people’s lives. Our goal is to
integrate cutting-edge automation, connectivity, big data, and
artificial intelligence technologies that bridge the gap between tools
and humans and transform people’s home cleaning experience.”
True Intelligence
PURE ONE is the first smart, cordless vacuum cleaner in the industry
that is equipped with a sensor that can detect dust amount and adjust
suction power in real time, integrating with artificial intelligence and
allowing vacuum cleaners to truly transform from functional to smart
devices in all aspects.
- Smart Suction Optimization
With built-in intelligence, the iLoop sensor detects dirt as small as
15 µm, and automatically adjusts suction power based on the real-time
dust amount. This changes the cumbersome procedure of manually adjusting
the suction of the traditional, functional vacuum cleaner and allows
consumers to complete an effortless, deep-through clean.
- Smart Battery Management
The intelligent battery management system allows the product to
independently adjust the energy consumption with up to 100 minutes of
battery life, achieving a breakthrough in the industry.
- Smart Rinse-free Filter Self Cleaning Tool
PURE ONE is equipped with a Powered Rinse-free Filter Cleaning Tool,
which ensures persistent suction power and device durability overtime.
The proprietary Tineco tool cleans the filter instantly and turns off
automatically after finished so consumers don’t need to manually wash
the filter and wait for it to air dry or replace with a new one.
- Smart Noise Control
With optimized suction power and advanced noise control system, the
vacuum noise is well controlled to as low as 71dB(A). Consumers can also
use the entertainment feature on the app to listen to music or watch
YouTube videos while cleaning with no noise distraction.
- All-in-one LED Display
The device’s LED display shows the device’s work logs like dust
condition, suction power, battery life, filter condition, and
malfunction issues on one screen, allowing users to see all working
status at a glance.
- Smart App Integration
Available for download on the Apple App and Google Play stores, the
Tineco Application integration allows users to control the vacuum
wirelessly. Consumers can monitor cleaning performance, track cleaning
reports, receive maintenance reminders and solutions, and more.
Outstanding Performance
Built with a 450W high-power digital motor, Tineco’s PURE ONE enables a
groundbreaking maximum suction power of 150W. With its V-shape, hard and
soft bristle direct-drive LED multi-tasker power brush, PURE ONE is able
to take either surface or embedded dirt with a power of 87 percent
higher than its predecessor, the A10 Hero. This increased performance is
ideal for larger particles, which oftentimes cause barriers or cleaning
challenges for everyday consumers.
The high-efficiency particulate air (HEPA), high voltage (HV) composite
cotton, metal etching net, cyclone separation four-filter system, which
efficiently and effectively filters out dust and harmful substances
layer-by-layer and intercepts approximately 99.99 percent of dirt, a
best-in-class filtration efficiency. This successfully avoids secondary
pollution and enables a purely clean experience for the entire home.
Sleek and Premium Design
PURE ONE is easily integrated into home settings, with its luxurious
etched design, grainy texture and mirror-plated trimming. The alloy
pipettes are not only lightweight, but more durable – enabling high
performance without compromising the aesthetics of the appliance in the
home. Light and convenient, PURE ONE’s main body weighs about 3.53
pounds, includes several out-of-box pieces with customized features such
as the 2-in-1 dusting brush and the soft dusting brush ensuring each
surface within the home receives a customized cleaning experience. The
combination of multiple brush heads also meets the requirements of
multi-scene applications for home cleaning, allowing consumers to easily
move between carpets, flooring, and other surfaces seamlessly.
The three Tineco PURE ONE models PURE ONE S12 M ($499 USD), PURE ONE S12
($599 USD), and PURE ONE S12 Plus ($699 USD) are currently available for
sale on Amazon.com.
PURE ONE S12 M |
PURE ONE S12 |
PURE ONE S12 Plus |
|||||||
Size | 30*15*6.6Inches | 33*15*6.6Inches | 33*15*6.6Inches | ||||||
Weight | 3.53 pounds (body) | 3.53 pounds (body) | 3.53 pounds (body) | ||||||
Color | Light Blue | Matte Black | Metallic Gray | ||||||
Run Time |
18-80min
with non-motorized tools |
21-100min
with non-motorized tools |
21-100min with non-motorized tools |
||||||
Battery Capacity | 2000mAh*2 | 2500mAh*2 | 2500mAh*2 | ||||||
LED Display | No | Yes | Yes | ||||||
Accessories |
Full-size LED multi-tasker power brush Mini power brush 2-in-1 dusting brush, Crevice tool Soft dusting brush Flexible long crevice tool Pre-filter cleaning tool + Extra pre-filter Hair cleaning tool Multi-angle folding adaptor Smart WiFi camera Smart bluetooth speaker |
Direct-drive LED multi-tasker power brush Mini power brush 2-in-1 dusting brush Crevice tool Soft dusting brush Flexible long crevice tool Automatic pre-filter cleaning tool + Extra pre-filter Hair cleaning tool |
Direct-drive LED multi-tasker power brush Mini power brush 2-in-1 dusting brush Crevice tool Soft dusting Brush Flexible long crevice tool LED soft-roller power brush Multi-angle folding tube Flexible extension hose Automatic pre-filter cleaning tool + Extra pre-filter Hair cleaning tool |
||||||
Max. Suction Power | 150AW | 150AW | 150AW | ||||||
Sensor Integration | Yes | Yes | Yes | ||||||
Noise | 71dB (A) | 71dB (A) | 71dB(A) | ||||||
Filter Efficiency | 99.99 percent | 99.99 percent | 99.99 percent | ||||||
Dustbin Capacity | 0.6L | 0.6L | 0.6L | ||||||
App Integration | Yes | Yes | Yes | ||||||
Rinse-free filter cleaning tool | Yes (manual) | Yes (powered) | Yes (powered) | ||||||
Storage | Dual battery charger + wall mount with 3 accessories on board | Dual battery charger + wall mount with 3 accessories on board | Dual battery charger + wall mount with 3 accessories on board | ||||||
To learn more about the Tineco PURE ONE product series, visit https://us.tineco.com/products/pure-one-s12.
About Tineco
Tineco is a technology innovation company specializing in intelligent
technology, a premium brand in smart electrical appliance. On March 13,
2019, Tineco launched the first smart vacuum cleaner, and became the
pioneer of the category. Founded in 1998, with the invention of its
first vacuum cleaner, Tineco obtained hundreds of domestic and
international patents and generated impressive sales globally.
Tineco takes “Live Easy, Enjoy Life” as its brand vision and firmly
believes that smart technology can improve people’s quality of life by
making cleaning an easy and joyful experience. For more information,
please visit https://www.tineco.com
Contacts
Allison DeLeo
Racepoint Global for Tineco
+1 415-694-6700
[email protected]
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
Innocan
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
![innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options](https://grassnews.net/wp-content/uploads/2024/08/61828-innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options.jpg)
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
![](https://grassnews.net/wp-content/uploads/2024/08/europe-medical-cannabis-market-forecast-2024-2032-tilray-aurora-cannabis-and-gw-pharmaceuticals-dominate-the-market-landscape.gif)
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks ago
Silly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks ago
Cannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week ago
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days ago
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder